MDG1 — Medigene AG Income Statement
0.000.00%
Last trade - 00:00- €2.51m
- -€8.97m
- €6.03m
Annual income statement for Medigene AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.6 | 8.75 | 11 | 31.2 | 6.03 |
| Cost of Revenue | |||||
| Gross Profit | 10.2 | 7.46 | 9.63 | 29.3 | 4.39 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 30.8 | 37.4 | 21 | 40 | 22.2 |
| Operating Profit | -20.2 | -28.7 | -9.98 | -8.73 | -16.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19.9 | -28.4 | -10.3 | -9.37 | -16.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -20 | -28.9 | -9.98 | -8.33 | -16.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -20 | -28.9 | -9.98 | -8.33 | -16.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -20 | -28.9 | -9.98 | -8.33 | -16.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.54 | -2.12 | -0.772 | 0.381 | -1.25 |
| Dividends per Share |